Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2000-5-15
pubmed:abstractText
1. We studied the functional interaction between transport and metabolism by comparing the transport of losartan and its active metabolite EXP 3174 (EXP) across cell monolayers. 2. Epithelial layers of Caco-2 cells as well as MDR1, MRP-1 and MRP-2 overexpressing cells, in comparison to the respective wildtypes, were used to characterize the transcellular transport of losartan and EXP. 3. Losartan transport in MDCK-MDR1 and Caco-2 cells was saturable and energy-dependent with a significantly greater basolateral-to-apical (B/A) than apical-to-basolateral (A/B) flux (ratio=31+/-1 in MDCK-MDR1 and ratio 4+/-1 in Caco-2 cells). The B/A flux of losartan was inhibited by cyclosporine and vinblastine, inhibitors of P-glycoprotein and MRP. In contrast, no active losartan transport was observed in MRP-1 or MRP-2 overexpressing cells. 4. The metabolite was only transported in Caco-2 cells with a B/A-to-A/B ratio of 5+/-1, while lacking active transport in the MDR1, MRP-1 or MRP-2 overexpressing cells. The B/A flux of EXP was significantly inhibited by cyclosporine and vinblastine. 5. In conclusion, losartan is transported by P-glycoprotein and other intestinal transporters, that do not include MRP-1 and MRP-2. In contrast, the carboxylic acid metabolite is not a P-glycoprotein substrate, but displays considerably higher affinity for other transporters than losartan, that again most probably do not include MRP-1 and MRP-2.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-10353984, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-1352222, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-1673839, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-2213556, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-2217530, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-2898143, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-7493917, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-7619215, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-7736913, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-7894497, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8100632, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8100817, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8104485, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8254497, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8372104, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8529329, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8636432, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8732283, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8820426, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8832062, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-8895755, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-9073310, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-9232527, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-9283689, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-9616186, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-9618413, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-9706044, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-9794492, http://linkedlifedata.com/resource/pubmed/commentcorrection/10725273-9794919
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
129
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1235-43
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:10725273-2,4-Dinitrophenol, pubmed-meshheading:10725273-Angiotensin II, pubmed-meshheading:10725273-Animals, pubmed-meshheading:10725273-Anti-Arrhythmia Agents, pubmed-meshheading:10725273-Antimetabolites, pubmed-meshheading:10725273-Biological Transport, Active, pubmed-meshheading:10725273-Caco-2 Cells, pubmed-meshheading:10725273-Cell Line, pubmed-meshheading:10725273-Chromatography, Liquid, pubmed-meshheading:10725273-Dogs, pubmed-meshheading:10725273-Energy Metabolism, pubmed-meshheading:10725273-Epithelium, pubmed-meshheading:10725273-Humans, pubmed-meshheading:10725273-Imidazoles, pubmed-meshheading:10725273-Kidney, pubmed-meshheading:10725273-Kinetics, pubmed-meshheading:10725273-LLC-PK1 Cells, pubmed-meshheading:10725273-Losartan, pubmed-meshheading:10725273-Mass Spectrometry, pubmed-meshheading:10725273-Swine, pubmed-meshheading:10725273-Temperature, pubmed-meshheading:10725273-Tetrazoles
pubmed:year
2000
pubmed:articleTitle
Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers.
pubmed:affiliation
Department of Biopharmaceutical Sciences, School of Pharmacy, University of California, San Francisco, CA 94143-0446, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't